Consequently, it is suggested that YPPP-treated CD11c+I-A/I-Ehigh cells may exbibit and contribute anti-tumor effect in vivo.Our data showed that in vivo anti-tumor activity of YPPP-DCV was superior to that of DMSO-DCV in E.G7 or B16 melanoma-bearing mouse models. This evidence concerns the gene ITGAX and melanoma.